

Mast cells are upregulated in Hidradenitis Suppurativa Tissue, associated with epithelialized tunnels and normalised by Spleen Tyrosine Kinase Antagonism.

A Flora^{1,2,3}, R Jepsen⁴, EK Kozera^{2,3}, JA Woods^{2,3}, GD Cains^{2,3}, M Radzieta^{5,6}, SO Jensen⁶ M Malone^{5,6}, JW Frew^{1,2,3,4}

1 Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, Australia.

2 University of New South Wales, Sydney, Australia

3 Department of Dermatology, Liverpool Hospital, Sydney, Australia

4 Holdsworth House Medical Practice, Sydney, Australia

5 South West Sydney Limb Preservation and Wound Research. Ingham Institute for Applied Medical Research

6 School of Medicine, Western Sydney University, Sydney, Australia

Abstract Word Count: 208

Word Count: 1921

Figure Count: 5

Supplementary File Count: 6

Corresponding Author

Dr John W. Frew

Laboratory of Translational Cutaneous Medicine,

Department of Dermatology, Liverpool Hospital

Suite 7, Level 1, 45-47 Goulburn St,

Liverpool NSW 2170

Ph: +61 2 87384560

Fax: +61 2 87384639

Email: john.frew@unsw.edu.au

Keywords: Hidradenitis Suppurativa, Mast Cells, SYK, Acne Inversa, Pathogenesis, Inflammation, Immunology, Innate Immunity

Funding: Nil

Disclosure Statement:

JWF has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie, Azora, Novartis and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Azora and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche Posay.

Data Availability:

Baseline RNA sequencing Data is publicly available using SRA Bioproject ID: PRJNA912704

Nanostring Data is publicly available using GEO Accession Number: GSE220454

CRedit Statement:

Akshay Flora: Investigation, Methodology, Visualization, Writing- Revision

Rebecca Jepsen: Investigation, Methodology, Writing- Revision

Emily Kozera: Methodology, Writing-Revision

Jane Woods: Methodology, Writing-Revision

Geoff Cains: Methodology, Writing- Revision

Michael Radzieta: Investigation Data Curation, Formal Analysis, Methodology, Writing- Revision

Slade Jensen: Funding Investigation, Writing-Revision

Matthew Malone: Investigation, Data Curation, Methodology, Writing- Revision

John Frew: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing-Original Draft Preparation

ORCID ID:

Akshay Flora: 0000-0001-7031-2710

Rebecca Jepsen: 0000-0002-7443-8748

Emily Kozera: 0000-0001-8311-9899

Jane Woods: 0000-0002-7459-2702

Geoff Cains: 0000-0002-7775-1502

Michael Radzieta: 0000-0002-7539-5479

Slade Jensen: 0000-0003-4489-589X

Matthew Malone: 0000-0002-2946-8841

John Frew: 0000-0002-5042-3632

ABSTRACT

Mast cells have traditionally been associated with allergic inflammatory responses; however they play important roles in cutaneous innate immunity and wound healing. The Hidradenitis Suppurativa tissue transcriptome is associated with alterations in innate immunity and wound healing associated pathways, however the role of Mast cells in the disease is unexplored. We demonstrate that Mast cell associated gene expression (using whole tissue RNAseq) is upregulated, and in-silico cellular deconvolution identifies activated mast cells upregulated and resting mast cells downregulated in lesional tissue. Tryptase/Chymase positive Mast cells (identified using IHC) localize adjacent to epithelialised tunnels, fibrotic regions of the dermis and at perivascular sites associated with Neutrophil Extracellular Trap formation and TNF-alpha production.

Treatment with Spleen Tyrosine Kinase antagonist (Fostamatinib) reduces the expression of mast cell associated gene transcripts, associated biochemical pathways, and number of tryptase/chymase positive mast cells in lesional hidradenitis suppurativa tissue.

This data indicates that although Mast cells are not the most abundant cell type in Hidradenitis Suppurativa tissue, the dysregulation of mast cells is associated with B cell/plasma cell inflammation, inflammatory epithelialized tunnels and epithelial budding. This provides an explanation as to the mixed inflammatory activation signature seen in HS, the correlation with dysregulated wound healing and potential pathways involved in the development of epithelialized tunnels.

INTRODUCTION

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease characterised by painful inflammatory nodules, deep-seated abscesses and chronically draining epithelialized tunnels with a predilection with flexural skin^{1,2}. The inflammatory transcriptome of tissue in HS includes a combination of Th17 dysregulation, B cell, plasma cell and immunoglobulin production as well as transepithelial neutrophil migration in epithelialized tunnels³⁻⁶. The precise pathogenesis of the disease is incompletely understood, although features of HS have known overlaps with other diseases including Psoriasis Vulgaris⁷, impaired wound healing³, as well as the fibroinflammatory features of diseases such as Scleroderma and Rheumatoid Arthritis^{8,9}.

Both impaired wound healing and fibroinflammatory disorders illustrate dysregulated mast cell function, cross talk with B cells and interaction with fibroblasts^{10,11}. These complex interactions lead to further activation of pro-inflammatory pathways and production of cytokines including IL-1B, IL-6 and IL-8¹⁰⁻¹⁵. Mast cells are associated with cathelicidin production in rosacea¹⁵ and play important roles in impaired cutaneous epithelialization and hypertrophic scar formation.^{11-14,16} Both of these characteristics are central features in HS. Mast cells have been identified as upregulated in HS lesional skin as well as associated with pruritus in the disease^{17,18}.

Whilst immunoglobulin E (IgE) and histamine are the most well-recognised triggers and products of mast cells respectively, mast cells are capable of responding to microbiological triggers through lectin binding receptors and direct production of a wide array of pro-inflammatory cytokines including TNF- α ^{14,15,19-21}. Alterations in lectin binding are associated

with recurrent infections, autoinflammatory disease and have been reported coexistent with HS which suggest a potential role for non-IgE mast cell pathways as contributory in HS.

Novel therapeutic targets in HS have focused upon targeting B cells as well as small molecules associated with multiple inflammatory pathways. One of these potential small molecules of interest is spleen tyrosine kinase (SYK), associated with mast cells, B cells, plasma cells, and cells of the monocyte lineage¹⁹⁻²¹.

In this study we aimed to assess the presence and characteristics of Mast cells in HS lesional tissue compared to non-lesional tissue and healthy controls. Additionally, the impact of SYK antagonism with Fostamatinib (as part of the Phase 2 clinical trial of Fostamatinib in HS NCT05040698) upon the presence and activity of mast cells was assessed using gene expression profiles and immunohistochemical markers in HS lesional tissue.

MATERIALS AND METHODS

Patients and Tissue Collection:

This study was approved by the human research ethics committee of Sydney South West Area Health Service (Sydney Australia). A total of 20 participants underwent lesional and non lesional biopsies (6mm in diameter) based upon previously published definitions^{24,25}. All. Biopsies were immediately stored in RNA Later and frozen at -80C until processing. Standard wound care was

undertaken for each of the biopsy sites. All patients were not on any active therapy at the time of biopsies. The clinical characteristics of participants are included in Supplementary Data.

Skin Biopsy mRNA Quantification:

Total RNA was extracted using the Qiagen RNeasy kit as per standard protocol (Qiagen, Valencia, CA, USA). RNA was sequenced using the Novaseq S4 (Illumina, San Diego, CA, USA). Differential expression was estimated with DESeq2 and VST to $\log_2$ transform the normalized counts. Differentially expressed genes were defined as fold change (FCH) of ≥ 1.5 and false discovery rate ≤ 0.05 .

Pathway Analysis:

Enrichment analyses were completed using Protein ANalysis THrough Evolutionary Relationships (PANTHER) classification system (www.pantherdb.org). Analyses were performed using whole tissue RNAseq data (Figure 1) as well as for Nanostring Gene Expression Panels. Nanostring gene expression panels included Baseline (prior to fostamatinib administration) and Week 4 of fostamatinib therapy lesional tissue samples (Figure 5).

CIBERSORTx:

In silico deconvolution was undertaken using the CIBERSORTx web application (<https://cibersortx.stanford.edu/index.php>) in order to estimate the abundance of immune cell and mast cell subpopulations in baseline lesional and non-lesional tissue using whole tissue RNAseq. The utilized immune cell reference matrix was based upon previously published

human skin scRNAseq data (GSE65136) with stratification into immune cell subsets a previously defined.

Nanostring Analysis:

Extracted RNA was analysed using the NCounter system (Nanostring) using the Human Fibrosis V2.0 gene panel. Raw data was processed using the Nanostring Nsolver (version 4.0.70) analysis software using quality control and normalization procedures derived from the NormqPCR R package as previously described²⁶. Differentially expressed genes (DEGs) were defined as >1.5 Log2Fold change with a false discovery rate<0.05 and p value<0.05.

Immunohistochemistry:

IHC staining was undertaken using primary antibodies listed in Supplementary Files. Stained slides underwent semiquantitative analysis using standardized, previously published methods²⁷. Differences between groups were analyzed using the Wilcoxon rank sum test for two variables and/or omnibus test using one-way ANOVA with adjustment for multiple comparisons was made using the Benjamini Hochberg procedure.

Statistical Analysis:

RNA sequencing statistical analysis was performed in R language (www.r-project.org; R Foundation, Vienna, Austria) using publicly available packages (www.bioconductor.org). Means of each group and differences between groups were estimated using least-square means. Hypothesis testing was undertaken using the general framework for linear mixed-effect models

of the limma package. tissue was considered a fixed factors while random effect related to subjects was included. Unsupervised clustering was performed with the Euclidean distance and average agglomeration. RNAseq data *P*-values were corrected for multiplicity using Benjamini–Hochberg procedure.

RESULTS:

RNA sequencing demonstrates upregulation of Mast cell associated gene signatures including FCAR, CCL3, OSM as well as Mast cell associated pathways.

Whole tissue RNAseq from lesional and non-lesional tissue from 20 individuals with HS (clinical and demographic data of included participants are included in Supplemental Data) identified differentially expressed genes associated with mast cell activity including *FCAR*, *CCL4*, *CCL7*, *CCL3*, *CXCL1* and *OSM* (Figure 1a,b). Pathway analysis demonstrated positive enrichment of pathways associated with regulation of mast cell activation, FC epsilon receptor signaling and regulation of response to wounding (Figure 1c). A full list of differentially expressed genes is included in Supplementary Data.

In Silico Deconvolution Analysis Identifies Significant Increases in activated mast cells in lesional tissue of HS compared to non-lesional skin

Using CibersortX, in silico deconvolution of whole tissue RNAseq was used to identify transcriptomic signatures indicative of mast cell activation (Figure 2). Whilst no significant difference in overall mast cell proportions was identified, the proportion of resting mast cells was significantly decreased in lesional tissue compared with non-lesional tissue (Figure 2b).

Additionally, the proportion of activated mast cells were significantly elevated in lesional tissue compared to non lesional tissue (Figure 2b).

Immunohistochemistry identifies Mast cell clustering around folliculosebaceous units, and epidermal budding with significantly increased numbers of mast cells in lesional and perilesional tissue.

Immunohistochemical (IHC) staining for mast cells validates the results seen in RNA sequencing and CIBERSORTX in-silico deconvolution analysis. IHC staining identified presence of mast cells adjacent to pilosebaceous units (Figure 3a) in lesional, perilesional and non-lesional tissue. Increased numbers of mast cells were identified alongside epithelial buds and active draining epithelialised tunnels (Figure 3b). Quantification of mast cell numbers demonstrated a statistically significant difference between lesional, perilesional and non-lesional tissue (Figure 3c). IHC staining with mast cell tryptase (Figure 3d) and mast cell chymase (Figure 3e) also demonstrated significant differences between the number of positive staining cells between lesional, perilesional and non-lesional tissue. Staining of serial sections identified mast cells expressing both mast cell tryptase and mast cell chymase (M_{CT}). Expression was present both in epidermal, dermal sections as well as surrounding epithelialised tunnels and tunnel-associated vasculature (Figure 4 and Supplementary Figure 1). M_{CT} cells were significantly more abundant in Hurley stage 3 patients compared to hurley stage 2 patients (Figure 4) as well as those patients with epithelialised tunnels compared to those without (Figure 4). Mast cells colocalized in the deep dermis surrounding vasculature with CD20+ B cells and CD138+ plasma cells as well as MPO+ neutrophils (Supplementary Figure 1).

Treatment with Spleen Tyrosine Kinase Antagonist Fostamatinib normalized Mast cell populations in lesional HS tissue, with decrease in Mast cell associated gene expression and pathways compared to baseline.

Spleen Tyrosine Kinase (SYK) inhibition with Fostamatinib at a dose of 100mg twice daily significantly reduced the presence of mast cells as measured by semiquantitative IHC (Figure 5a). The level of mast cells at week 4 of fostamatinib therapy was comparable to that in healthy controls and this effect was seen in both lesional tissue and perilesional tissue. Significant modulation of gene expression as measured by the Human Fibrosis V2.0 Nanostring gene expression assay was also noted at Week 4 compared to baseline (Figure 5b). Genes including *IL13*, *TRIB3*, *TSPAB1/2*, *FCER1G* and *RAC1* (involved with mast cell sensitisation and signalling) were significant downregulated at week 4 compared with baseline. Pathway analysis demonstrated high levels of enrichment associated with mast cell activation, mast cell degranulation and Fc-epsilon receptor signalling. (Figure 5c).

DISCUSSION

This study presents novel gene expression and immunohistochemical data pertaining to the presence of activated mast cells in lesional and perilesional tissue of Hidradenitis Suppurativa. In comparison to healthy controls and non-lesional tissue, mast cells are increased in number and activated mast cells are significantly upregulated in lesional compared to non-lesional tissue. Within biopsy specimens, mast cells are identified in areas surrounding the pilosebaceous unit, at the advancing edge of epithelial buds in the epidermis as well as to areas

surrounding epithelialised dermal tunnels. They also colocalise with B cells, plasma cells and neutrophils in the deep dermis surrounding vascular structures. This raises the prospect that mast cell activation may be involved with epithelial mesenchymal transition (EMT) which has been identified as present in HS lesions with epithelialised tunnels^{28,29}. The activity of mast cells in HS tissue has previously been described^{17,18}, however this study provides a much higher degree of resolution as to the localisation of mast cells as well as associations with clinical characteristics such as Hurley Staging and presence of epithelialised tunnels. The presence of mast cells may help explain pruritus in the disease, which is a largely underappreciated symptom of HS¹⁸.

RNA sequencing has illustrated similarities between the HS transcriptome and wound healing³, suggesting aberration in wound healing responses are involved in the pathogenesis of disease. Mast cells contribute to wound healing through EMT mechanisms, vascular dilatation and fibrinogenesis through release of various cytokines and chemokines³¹. Upregulation of S100 proteins and downregulation of Dermcidin are prominent features in the transcriptome of HS³. Evidence from in vitro studies have associated alterations in these products with variations in mast cell function and IL-6, IL-8 and TGF- β production³¹. This evidence, along with the localisation of mast cells at discrete areas in HS tissue suggest that their role may be less associated traditional allergic histamine responses and more associated with EMT, pro-fibrotic processes and influx of other inflammatory cells such as B cells, plasma cells and neutrophils³¹.

Mast cells are associated with fibrosis in various organ systems including the skin through production of TGF- β , IL-1, IL-33 and IL-8^{14,15}. They also demonstrate interactions with other inflammatory cells including B cells and modulate neutrophil influx from vasculature into tissue¹⁵. The colocalization of mast cells in HS patient with Hurley 3 disease and epithelialised tunnels, as well as HS tissue in areas associated with EMT, B cells and neutrophil activity all support the role of mast cells as supportive players in the complex inflammatory milieu of HS³². SYK antagonism with Fostamatinib demonstrated significant modulation of mast cell numbers and mast cell associated gene expression after four weeks of therapy. This, alongside the clinical efficacy demonstrated in our Phase 2 proof-of-concept study (NCT05040698) support the role of small molecular targets modulating multiple aspects of innate and humoral immunity in the treatment of HS. Future analysis of this clinical trial data will enable deeper investigation into the precise mechanisms of SYK inhibition in HS at higher doses and further timepoints.

Data Availability Statement:

Baseline RNA sequencing Data is publicly available using SRA Bioproject ID: PRJNA912704

Nanostring Data is publicly available using GEO Accession Number GSE220454

ORCID IDs:

Akshay Flora: 0000-0001-7031-2710

Rebecca Jepsen: 0000-0002-7443-8748

Emily Kozera: 0000-0001-8311-9899

Jane Woods: 0000-0002-7459-2702

Geoff Cains: 0000-0002-7775-1502

Michael Radzieta: 0000-0002-7539-5479

Matthew Malone: 0000-0002-2946-8841

John Frew: 0000-0002-5042-3632

Conflicts of Interest:

JWF has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, Abbvie and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Abbvie, Janssen, and received research support from Ortho Dermatologics and Sun Pharma and La Roche Posay

Acknowledgements: Nil

Author Contributions:

Akshay Flora: Investigation, Methodology, Visualization, Writing- Revision

Rebecca Jepsen: Investigation, Methodology, Writing- Revision

Emily Kozera: Methodology, Writing-Revision

Jane Woods: Methodology, Writing-Revision

Geoff Cains: Methodology, Writing- Revision

Michael Radzieta: Investigation Data Curation, Formal Analysis, Methodology, Writing- Revision

Matthew Malone: Investigation, Data Curation, Methodology, Writing- Revision

John Frew: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology,

Software, Visualization, Writing-Original Draft Preparation

REFERENCES

1. Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. *Nat Rev Dis Primers* 2020; 6(1): 18.
2. Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic and molecular evidence. *JAAD Int* 2020; 1(1): 62-72.
3. Coates M, Mariottoni P, Corcoran DL, Kirshner HF, Jaleel T, Brown DA, Brooks SR, Murray J, Morasso MI, MacLeod AS. The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin. *PLoS One*. 2019 May 6;14(5):e0216249.
4. Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. *J Allergy Clin Immunol*. 2022 Jan;149(1):135-144.e12.
5. Hoffman LK, Tomalin LE, Schultz G, Howell MD, Anandasabapathy N, Alavi A, Suárez-Fariñas M, Lowes MA. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. *PLoS One*. 2018 Sep 28;13(9):e0203672
6. Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. *J Allergy Clin Immunol*. 2021 Jun;147(6):2213-2224. doi: 10.1016/j.jaci.2020.12.651.

7. Navrazhina K, Garcet S, Frew JW, Zheng X, Coats I, Guttman-Yassky E, Krueger JG.
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. *J Am Acad Dermatol*. 2022 Feb;86(2):322-330.
8. Byrd AS, Carmona-Rivera C, O'Neil LJ, Carlucci PM, Cisar C, Rosenberg AZ, Kerns ML, Caffrey JA, Milner SM, Sacks JM, Aliu O, Broderick KP, Reichner JS, Miller LS, Kang S, Robinson WH, Okoye GA, Kaplan MJ. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. *Sci Transl Med*. 2019 Sep 4;11(508):eaav5908.
9. Frew JW, Navrazhina K, Marohn M, Lu PC, Krueger JG. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. *Exp Dermatol*. 2019 Aug;28(8):886-891. doi: 10.1111/exd.13978.
10. Artuc M, Steckelings M, Henz BM Mast-cell Fibroblast Interactions: Human mast cells as sources and inducers of fibroblast and epithelial growth factors. *J Invest Dermatol* 2002; 118; 391-395
11. Wilgus TA, Ud-Din S, Bayat A A Review of the Evidence for and against a Role for Mast cells in Cutaneous Scarring and Fibrosis. *Int J MolSci* 2020;21(24):9673
12. Strattan E, Palaniyandi S, Kumari R, Du J, Hakim N, Huang T, Kesler MV, Jennings CD, Sturgill JL and Hildebrandt GC (2019) Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease. *Front. Immunol.* 10:2470. doi: 10.3389/fimmu.2019.02470

13. Maurer M, Taube C, Schröder NWJ, Ebmeyer J, Siebenhaar F, Geldmacher A, Schubert N, Roers A. Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. *J Allergy Clin Immunol*. 2019 Oct;144(4S):S19-S30.
14. Mukai K, Tsai M, Saito H, Galli SJ Mast cells as sources of cytokines, chemokines and growth factors. *Immunological Reviews*: 2018;282(1):121-150
15. Dudek J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI et al Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation. *Immunity* 2021;54(3):468-483
16. Wu J, Del Duca E, Espino M, Gontzes A, Cueto I, Zhang N, Estrada YD, Pavel AB, Krueger JG and Guttman-Yassky E (2020) RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing. *Front. Immunol.* 11:597741. doi: 10.3389/fimmu.2020.597741
17. List, E.K., Pascual, J.C., Zarchi, K. *et al.* Mast cells in hidradenitis suppurativa: a clinicopathological study. *Arch Dermatol Res* **311**, 331–335 (2019). <https://doi.org/10.1007/s00403-019-01910-3>
18. Vossen ARJV, Schoenmakers A, van Straalen KR, Presn EP, van der Zee HH Assessing Pruritus in Hidradenitis SuppurativaL A Cross-Sectional Study. *Am J Clin Dermatol* 2017;18(5):687-695
19. Ud-Din S, Wilgus TA, Bayat A Mast cells in Skin Scarring: A Review of Animal and Human Research *Front Immunol* 2020 11:552205

20. Zhang S, Sumpter TL, Kaplan DH Neuron-Mast cell cross-talk in the skin J Invest Dermatol 2021; 142(3):841-848
21. Wang F, Yang TLB, Kim BS. The return of the Mast cell: New roles I neuroimmune itch biology. J Invest Dermatol 2020;140(5):940-945
22. Bhargava S, Becker N, Kroumpouzou G. Atypical Clinical Presentation of Hidradenitis Suppurativa in a Patient with Severe Mannose-Binding Lectin Deficiency. Case Rep Dermatol. 2020 May 5;12(2):83-91. doi: 10.1159/000507539.
23. Frew JW, Marzano AV, Wolk K, Join-Lambert O, Alavi A, Lowes MA, Piguet V. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. J Invest Dermatol. 2021 Feb;141(2):316-324.e2. doi: 10.1016/j.jid.2020.06.019.
24. Frew JW, Navrazhina K, Byrd AS, Garg A, Ingram JR, et al. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. Br J Dermatol 2019;181(6):13391-341
25. Frew JW, Lowes MA, Goldfarb N, Butt M, Piguet V, O'Brien E, Ingram J, Jemec GBE, Tan J, Zouboulis C, Alavi A, Kirby JS. Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. JAMA Dermatol. 2021 Apr 1;157(4):449-455. doi: 10.1001/jamadermatol.2020.5467.
26. Bhattacharya A, Hamilton AM, Furberg H, Pietzak E, Purdue MP, Troester MA, Hoadley KA, Love MI. An approach for normalization and quality control for NanoString RNA expression data. Brief Bioinform. 2021 May 20;22(3):bbaa163. doi: 10.1093/bib/bbaa163.

27. Crowe AR, Yue W. Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol. *Bio Protoc.* 2019 Dec 20;9(24):e3465. doi: 10.21769/BioProtoc.3465.
28. Visciano C, Liotti F, Prevete N, Cali' G, Franco R, Collina F, de Paulis A, Marone G, Santoro M, Melillo RM. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. *Oncogene.* 2015 Oct 1;34(40):5175-86
29. A Flora, R Jepsen, EK Kozera, JA Woods, GD Cains, M Radzieta, SO Jensen, MM Malone, JW Frew Human Dermal Fibroblast Subpopulations and Epithelial Mesenchymal Transition Signals in Hidradenitis Suppurativa Tunnels are Normalized by Spleen Tyrosine Kinase Antagonism in Vivo *bioRxiv* 2023.02.23.529664;
30. Bradding P, Pejler G. The controversial role of mast cells in fibrosis. *Immunol Rev.* 2018 Mar;282(1):198-231.
31. Komi DEA, Khomtchouk K, Santa Maria PL. A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms. *Clin Rev Allergy Immunol.* 2020 Jun;58(3):298-312.
32. Frew JW, Grand D, Navrazhina K, Krueger JG. Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets? *Exp Dermatol.* 2020 May;29(5):509-515. doi: 10.1111/exd.14092.

TABLES AND FIGURE LEGENDS:

Figure 1: Whole Tissue RNAseq demonstrated upregulation of genes associated with Mast cell activity in lesional tissue of HS compared to non-lesional tissue. (a): Heatmap demonstrating overall tissue transcriptome with highest DEG pertaining to B cell and keratinocyte related genes- Cytokines and proteins associated with Mast cell activity also dysregulated. (B): Volcano plot demonstrating the statistical significance of some mast cell associated genes which also overlap with possible other innate inflammatory activity

Figure 2: CibersortX In Silico Deconvolution Analysis Identifies Significant Increases in Mast cell and activated mast cells in lesional tissue of HS. (A): Individual deconvolution significant expansion of B cell, macrophage and CD4 T cell populations in lesional versus non lesional tissue. (B) but also a statistically significant decrease in resting mast cell and increase in activated mast cell populations (C).

Figure 3: Immunohistochemistry staining for Mast cells in Lesional and Non Lesional tissue demonstrating normal clustering around hair follicles, sebaceous glands in non-lesional unaffected tissue, with increased numbers of Mast cells around epithelial buds and active draining epithelialized tunnels.

Figure 4: Immunohistochemical staining for mast cell tryptase (a) and mast cell chymase (b) demonstrating increased numbers surrounding vasculature and tunnel epithelium, with numerically increased numbers in Hurley stage 3 patients compared to Hurley stage 2 patients, and biopsy specimens with epithelialised tunnels as opposed to without epithelialised tunnels.

Figure 5: (a) Semiquantitative immunohistochemical evaluation of skin biopsies at Week 0 and Week 4 after administration of 100mg BID of Fostamatinib demonstrating a significant reduction in mast cell numbers. (b) Gene expression profiling with Nanostring demonstrating significant reduction in Mast cell associated gene expression at Week 4 compared to Week 0. (c) Pathway analysis demonstrating reduction in mast cell associated pathways at Week 4 compared to baseline.

Supplementary Figure 1: Individual patient cell proportion data from CibersortX in-silico deconvolution examining mast cells in lesional and non-lesional tissue of Hidradenitis Suppurativa.

Supplementary Figure 2: Additional immunohistochemical staining demonstrating clustering of tryptase and chymase positive mast cells with CD20+ B cells, CD138+ plasma cells and MPO+ neutrophils surrounding dermal vasculature.

Supplementary Table 1: Patient Demographics and Disease Characteristics

Supplementary Table 2: Differentially Expression Genes in whole tissue RNAseq

Supplementary Table 3: Immunohistochemical Antibodies used in this study.

Supplementary Table 4: Differentially Expressed Genes in Nanostring Gene Expression Panel.









